ALL, Adult
14
1
6
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
1 terminated out of 14 trials
75.0%
-11.6% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (14)
Characterizing Sleep Among Long-term Survivors of Childhood Cancer
Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
A Study of BN104 in the Treatment of Acute Leukemia
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Video-recOrded hospItal dischaRge (VOIR)
Optimising Pharmacist-led Medication Reviews in Primary Care
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL